Cargando…

Safety and effectiveness of taliglucerase alfa in patients with Gaucher disease: an interim analysis of real-world data from a multinational drug registry (TALIAS)

BACKGROUND: Limited real-world data from routine clinical care are available on the safety and effectiveness of treatment with taliglucerase alfa in patients with Gaucher disease (GD). METHODS: Taliglucerase Alfa Surveillance (TALIAS), a multinational prospective Drug Registry of patients with GD, w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Titievsky, Lina, Schuster, Tilman, Wang, Ronnie, Younus, Muhammad, Palladino, Andrew, Quazi, Kabir, Wajnrajch, Michael P., Hernandez, Betina, Becker, Pamela S., Weinreb, Neal J., Chambers, Christina, Mansfield, Roy, Taylor, Louise, Tseng, Li-Jung, Kaplan, Paige
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8973565/ https://www.ncbi.nlm.nih.gov/pubmed/35365177 http://dx.doi.org/10.1186/s13023-022-02289-7

Ejemplares similares

Taliglucerase alfa: safety and efficacy across 6 clinical studies in adults and children with Gaucher disease
por: Zimran, Ari, et al.
Publicado: (2018)

Breastfeeding in patients with Gaucher disease: Is taliglucerase alfa safe?
por: Paskulin, Livia, et al.
Publicado: (2019)

Real-World Experiences with Taliglucerase Alfa Home Infusions for Patients with Gaucher Disease: A Global Cohort Study
por: Revel-Vilk, Shoshana, et al.
Publicado: (2023)

Spotlight on taliglucerase alfa in the treatment of pediatric patients with type 1 Gaucher disease
por: Gupta, Punita, et al.
Publicado: (2017)

An evidence-based review of the potential benefits of taliglucerase alfa in the treatment of patients with Gaucher disease
por: Hollak, Carla EM
Publicado: (2012)

Pharmacokinetics of Novel Plant Cell-Expressed Taliglucerase Alfa in Adult and Pediatric Patients with Gaucher Disease
por: Abbas, Richat, et al.
Publicado: (2015)

Improvement in bone marrow infiltration in patients with type I Gaucher disease treated with taliglucerase alfa
por: Zimran, Ari, et al.
Publicado: (2018)

Long‐term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment‐naïve patients with Gaucher disease
por: Zimran, Ari, et al.
Publicado: (2016)

First person – Talia Nasr
Publicado: (2021)

Enzyme replacement therapy with taliglucerase alfa: 36‐month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase
por: Pastores, Gregory M., et al.
Publicado: (2016)

Immunogenicity of glycans on biotherapeutic drugs produced in plant expression systems—The taliglucerase alfa story
por: Rup, Bonita, et al.
Publicado: (2017)

Rethinking fatigue in Gaucher disease
por: Zion, Y. Chen, et al.
Publicado: (2016)

Long-term safety and effectiveness of velaglucerase alfa in Gaucher disease: 6-year interim analysis of a post-marketing surveillance in Japan
por: Sagara, Rieko, et al.
Publicado: (2021)

Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry
por: Rosenbloom, Barry E., et al.
Publicado: (2022)

Comparative Therapeutic Effects of Velaglucerase Alfa and Imiglucerase in a Gaucher Disease Mouse Model
por: Xu, You-Hai, et al.
Publicado: (2010)

A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability
por: Pastores, Gregory M., et al.
Publicado: (2014)

The International Collaborative Gaucher Group GRAF (Gaucher Risk Assessment for Fracture) score: a composite risk score for assessing adult fracture risk in imiglucerase-treated Gaucher disease type 1 patients
por: Deegan, Patrick, et al.
Publicado: (2021)

The definition of neuronopathic Gaucher disease
por: Schiffmann, Raphael, et al.
Publicado: (2020)

Seven‐year safety and efficacy with velaglucerase alfa for treatment‐naïve adult patients with type 1 Gaucher disease
por: Zimran, Ari, et al.
Publicado: (2015)

Gaucher Disease and Gaucher Cells
por: Gözdaşoğlu, Sevgi
Publicado: (2015)

Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial
por: Wilkinson, P M, et al.
Publicado: (2006)

Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry
por: Mistry, Pramod K., et al.
Publicado: (2017)

Gaucher Disease in Bone: From Pathophysiology to Practice
por: Hughes, Derralynn, et al.
Publicado: (2019)

Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trials
por: Hughes, Derralynn A, et al.
Publicado: (2015)

The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). J. Clin. Med. 2022, 11, 5158
por: Mistry, Pramod K., et al.
Publicado: (2023)

Gaucher Cells or Pseudo-Gaucher Cells: That’s the Question
por: Gören Şahin, Deniz, et al.
Publicado: (2014)

Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism
por: Furderer, Makaila L., et al.
Publicado: (2022)

Retinal thinning in phenylketonuria and Gaucher disease type 3
por: Hopf, Susanne, et al.
Publicado: (2021)

A new framework for evaluating the health impacts of treatment for Gaucher disease type 1
por: Ganz, Michael L., et al.
Publicado: (2017)

Gaucher's disease
por: Bohra, Vijay, et al.
Publicado: (2011)

Gaucher’s Disease
Publicado: (1916)

Modeling potential interactions between oral Gaucher disease treatment and investigational COVID-19 therapies
por: Sahasrabudhe, Siddhee A., et al.
Publicado: (2021)

Patients with type 1 Gaucher disease in South Florida, USA: demographics, genotypes, disease severity and treatment outcomes
por: Orenstein, Marissa, et al.
Publicado: (2014)

Presenting signs and patient co‐variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED‐C) Delphi initiative
por: Mehta, Atul, et al.
Publicado: (2019)

PB2024: PREVALENCE OF TYPE 1 GAUCHER DISEASE IN PATIENTS WITH MULTIPLE MYELOMA: FIRST INTERIM ANALYSIS OF A PROSPECTIVE, MULTICENTER, OBSERVATIONAL STUDY
por: Offidani, M., et al.
Publicado: (2022)

Hepatocellular carcinoma in Gaucher disease: an international case series
por: Regenboog, Martine, et al.
Publicado: (2018)

Gaucher Disease: Transcriptome Analyses Using Microarray or mRNA Sequencing in a Gba1 Mutant Mouse Model Treated with Velaglucerase alfa or Imiglucerase
por: Dasgupta, Nupur, et al.
Publicado: (2013)

Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial
por: Pleat, Rebecca, et al.
Publicado: (2016)

Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials
por: Santagostino, E, et al.
Publicado: (2015)

Safety of Ovaleap® (Follitropin Alfa) in Infertile Women Undergoing Superovulation for Assisted Reproductive Technologies: A Multinational Comparative, Prospective Cohort Study
por: Kaplan, Sigal, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_55m5lv42lmek7lg6k6ugahn2hc